Elpis Biopharmaceuticals to Present Two "Late-Breaking" Posters Detailing Its Pioneering CAR-T Cell Therapy Technologies at AACR Annual Meeting 2025

Research highlights potential of EPC-002 in the treatment of solid tumors and EPC-003 for the treatment of glioblastoma

LEXINGTON, Mass. and SINGAPORE, April 28, 2025 /PRNewswire/ -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced that it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025. The presentations, which were accepted as late-breaking submissions, highlight the company's latest advances in multi-mechanism, armored CAR-T therapies for the treatment of solid tumors and glioblastoma (GBM).

The first poster, LB363, titled, "Multi-mechanism human B7H3 CAR-T effectively overcome tumor microenvironment resistance in treatment of solid tumors," details research involving EPC-002, Elpis's novel human B7H3-targeted CAR-T cell therapy developed with a proprietary, precision-engineered multi-mechanism armor to simultaneously overcome multiple tumor microenvironment (TME) resistant mechanisms. B7H3 is overexpressed on a wide range of solid tumors, including skin, pancreatic, lung, breast, colon, kidney, ovarian, and other cancers. As presented at AACR, EPC-002 demonstrated an ability to reduce regulatory T cell proliferation, modulate CAR-T and bystander immune cell activation, enhance TIL infiltration, overcome TME suppression, and mediate anti-tumor activity. These mechanisms were highlighted in preclinical mouse models in which EPC-002 enabled complete tumor regression and long-term persistence with very low dose of 0.3M CAR-T cells in tumor rechallenging studies.

The second poster, LB360, titled, "Discovery and development of fully human IL13Ra2/B7H3 bispecific armored CAR-T for treatment of glioblastoma," describes the ongoing development of EPC-003, Elpis's first-in-class human bispecific CAR-T cell therapy targeting IL13Ra2 and B7H3, two antigens co-expressed in a majority of GBM tumors. Engineered with Elpis's proprietary mRNADis™ and mSCAFold™ platforms, EPC-003 integrates dual antigen targeting with a secreted multi-functional armor to enhance CAR-T cell persistence, block immune suppression, and penetrate the blood-brain barrier (BBB). As presented at AACR, in an orthotopic GBM mouse model, EPC-003 induced tumor regression as early as day 6 following intracranial injection of 2 × 10⁶ CAR-T cells. Moreover, intravenous injected CAR-T cells successfully penetrated the BBB, achieving significant tumor regression by day 13 post-treatment.

"Having two presentations detailing our lead product candidates, EPC-002 and EPC-003, accepted as late-breaking submissions at AACR is tremendous validation of Elpis's technologies and the potential that each offers in the treatment of solid tumors and glioblastoma, which have thus far proven resistant to most CAR-T therapies," said Yan Chen, MD, Ph.D., CEO of Elpis Biopharmaceuticals. "Our multi-mechanism approach is designed to address the challenges of tumor microenvironment resistance and antigen heterogeneity, unlocking the full potential of CAR-T in solid tumors and hard-to-treat cancers like glioblastoma. We now look forward to advancing each product into the clinic, including a soon-to-be initiated proof of concept, investigator-initiated trial of EPC-003 in resistant/relapsed glioblastoma patients."

Presentation Details:

About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis's lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Lexington, MA and Singapore. For more information, visit www.elpisbiopharmaceuticals.com.

Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent (investors)
+1-205-566-3026
[email protected]

Eric Reiss (media)
[email protected]

SOURCE Elpis Biopharmaceuticals